Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Kapoor P, et al. Among authors: lust ja. Blood. 2009 Jul 16;114(3):518-21. doi: 10.1182/blood-2009-01-202010. Epub 2009 Mar 26. Blood. 2009. PMID: 19324902 Free PMC article.
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A. Khan ML, et al. Br J Haematol. 2012 Feb;156(3):326-33. doi: 10.1111/j.1365-2141.2011.08949.x. Epub 2011 Nov 23. Br J Haematol. 2012. PMID: 22107129 Free article.
Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, Gonsalves WI, Leung N, Dispenzieri A, Kourelis TV, Go RS, Lacy MQ, Hobbs MA, Lin Y, Warsame R, Lust J, Fonder AL, Hwa YL, Hayman SR, Russell SJ, Kyle RA, Gertz MA, Kapoor P. Lakshman A, et al. Am J Hematol. 2017 Nov;92(11):1146-1155. doi: 10.1002/ajh.24883. Epub 2017 Sep 8. Am J Hematol. 2017. PMID: 28799231 Free article.
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.
Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A. Warsame R, et al. Blood Cancer J. 2020 Jan 8;10(1):4. doi: 10.1038/s41408-019-0266-9. Blood Cancer J. 2020. PMID: 31913261 Free PMC article.
Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV, Kumar SK. Abdallah N, et al. Blood Adv. 2020 Aug 11;4(15):3509-3519. doi: 10.1182/bloodadvances.2020002218. Blood Adv. 2020. PMID: 32750129 Free PMC article.
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.
Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Abdallah N, et al. Blood Cancer J. 2020 Aug 11;10(8):82. doi: 10.1038/s41408-020-00348-5. Blood Cancer J. 2020. PMID: 32782240 Free PMC article.
Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.
Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Abdallah N, et al. Clin Cancer Res. 2020 Dec 15;26(24):6581-6588. doi: 10.1158/1078-0432.CCR-20-2283. Epub 2020 Oct 2. Clin Cancer Res. 2020. PMID: 33008815 Free PMC article.
Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma.
Tschautscher MA, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell SJ, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Vincent Rajkumar S, Kumar S. Tschautscher MA, et al. Blood Cancer J. 2020 Oct 2;10(10):95. doi: 10.1038/s41408-020-00363-6. Blood Cancer J. 2020. PMID: 33009363 Free PMC article. No abstract available.
Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma.
Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Broski SM, Rajkumar V, Kumar S. Kaddoura M, et al. Blood Adv. 2021 Jul 13;5(13):2753-2759. doi: 10.1182/bloodadvances.2020004131. Blood Adv. 2021. PMID: 34242392 Free PMC article.
282 results